[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fLnkb0bpeUSmjncJKaHQ9czLsLXdInZyHAb_prh1XjCQ":8,"$fTSBmR2_88RTyl8RGC6lWGMmtF6V5JozmNiqGv97MhOY":55,"$fhP8QrXXA98VhSzAHFOL0jxMHw8HdbFn7eONqfJ__2nU":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},63611,870358,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//KGvUiQyxX7cgFOiNjW883bSOhp4xZi3T.png","罗旭","大连医科大学附属第一医院","肝胆外科","住院医师",53,0,"胰腺癌与肝转移：化疗方案新进展全解——药品安全用药实用指南","","https://ystcdn.venuertc.com/venue/AI/9f0d05d4-1d21-4211-8130-b1bf0de838db.jpg","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  胰腺癌与肝转移：化疗方案新进展全解——药品安全用药实用指南\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 用药方案简介 🧬\u003C/h2>\n    \u003Cp>\n      说起来，针对胰腺癌肝转移，常见的化疗药物有吉西他滨（Gemcitabine）、白蛋白结合型紫杉醇（Nab-paclitaxel）、FOLFIRINOX组合（含5-氟尿嘧啶、奥沙利铂、伊立替康、亚叶酸钙）等。这些药品在晚期实体瘤的化疗中发挥着重要作用。本文将重点讲解7个用药细节，让大家用得明白、用得安全。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药理作用机制速览⚗️\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>吉西他滨\u003C/strong>是一种嘧啶类似物，通过抑制DNA合成而阻断肿瘤细胞的分裂增殖。\u003Cbr>\n      \u003Cstrong>白蛋白紫杉醇\u003C/strong>的主要机制是干扰微管结构，使分裂细胞无法完成有丝分裂。蛋白包裹有助于更好地进入肿瘤组织。\u003Cbr>\n      \u003Cstrong>FOLFIRINOX方案\u003C/strong>由四种药物组成，协同抑制DNA和RNA的复制，对多种肿瘤细胞有杀灭作用。\n      \u003Cbr>\n      这些药品各有机制，实际使用时通常会联合应用以提高化疗效果。[Ouyang H, Pan Z, Xie G. Advances in the treatment of pancreatic cancer with liver metastasis. \u003Cem>Frontiers in Oncology\u003C/em>, 2021.]\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 剂型特点与服药方法🌗\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>吉西他滨\u003C/strong>：常见为注射剂型，按照体表面积（m²）换算剂量，通过静脉滴注给药。\u003Cbr>\n      \u003Cstrong>紫杉醇\u003C/strong>：也是注射剂，通过缓慢静滴，首剂通常需低速，避免急性反应。\u003Cbr>\n      \u003Cstrong>FOLFIRINOX全套\u003C/strong>：多为联合输液，具体分药顺序，有时需留置静脉导管。\u003Cbr>\n      正确做法：\u003Cbr>\n      - 药品需严格按照方案制定间隔周期和剂量。\u003Cbr>\n      - 需配专业医疗人员操作，家用不得自行处理。\n    \u003C/p>\n    \u003Cdiv class=\"drug-box-emoji\">💉💧\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 用药时间和注意事项⏰\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>服药时间\u003C/strong>：周期性化疗一般每2~3周1次，每个周期间休息若干天，避免累计毒性。\u003Cbr>\n      \u003Cstrong>服药前准备\u003C/strong>：务必检查血象、肝肾功能。\u003Cbr>\n      \u003Cstrong>饮水和进食\u003C/strong>：输液当天不忌口，但需避免空腹给药。补液有助于减轻药物刺激。\n      \u003Cbr>\n      特别提醒：\u003Cbr>\n      - 高龄患者、肾功能不全者剂量需个体化调整。\u003Cbr>\n      - 如遇特殊症状（例如发热、血象过低），应立即告知医师暂停或改期。\n    \u003C/p>\n    \u003Cdiv class=\"drug-box-emoji\">🔔🥛\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用分析🔗\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>吉西他滨\u003C/strong>和\u003Cem>紫杉醇\u003C/em>等药品，在与其他骨髓抑制类药物（如氟尿嘧啶、放化疗联合药物）联合时，会增加骨髓抑制风险，须密切监测血象。\u003Cbr>\n      \u003Cstrong>紫杉醇\u003C/strong>：不能与头孢类抗生素等部分药物混合注射，可能发生沉淀。\u003Cbr>\n      \u003Cstrong>FOLFIRINOX\u003C/strong>：方案各药物需按顺序，每种药品之间不得混合推注。\n      \u003Cbr>\n      正确做法：\n      \u003C/p>\u003Cul>\n        \u003Cli>结合法规定科室用药流程，严格遵医嘱。\u003C/li>\n        \u003Cli>告知医生所有正在用药品，避免药物冲突。\u003C/li>\n      \u003C/ul>\n      \u003Cspan>卡铂、顺铂等部分化疗药物，在组合化疗时与上述药物存在协同作用，也可能诱发增强不良反应，须谨慎评估。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 特殊人群用药细节🧓👵\u003C/h2>\n    \u003Cp>\n      老年患者（如70岁女性，体重70kg，案例中血压正常控制）用药需考虑代谢减慢、器官储备下降：\u003Cbr>\n      - 化疗剂量往往需下降至常规剂量的75%~85%。\u003Cbr>\n      - 必须强化血象、肝肾监测，尤其首周期及调整方案后2周重点复查。\u003Cbr>\n      - 联合用药方案，选药应避免重复机制和增强毒副反应。\u003Cbr>\n      孕妇和哺乳期禁用所有上述药品，生育计划者停药后至少半年内才可妊娠。[Conroy T et al., \"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer\", \u003Cem>NEJM\u003C/em>, 2011.]\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 常见不良反应与处理方法❗\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>骨髓抑制：\u003C/strong>如出现白细胞、血小板下降，须暂停化疗并加强护肝、血象支持。\u003Cbr>\n      \u003Cstrong>消化道反应：\u003C/strong>常见恶心、腹泻，可用止吐、止泻药辅助。\u003Cbr>\n      \u003Cstrong>脱发：\u003C/strong>多数患者半年内出现，属于可逆过程。\u003Cbr>\n      \u003Cstrong>神经毒性：\u003C/strong>奥沙利铂、伊立替康常导致手指发麻、刺痛。\u003Cbr>\n      \u003Cstrong>过敏：\u003C/strong>紫杉醇有少数急性过敏风险，首剂需有急救药物备份。\n      \u003Cbr>\n      正确做法：\u003Cbr>\n      - 如出现发热、严重出血、皮疹及时就医。\u003Cbr>\n      - 不良反应可预防性用药，如早期止吐药或升白细胞药品。\n      \u003Cbr>\n      临床数据：FOLFIRINOX方案不良反应发生率在45%以上，吉西他滨-紫杉醇组合略低，但骨髓抑制发病率依然需警惕。[Neuzillet C et al., \"Standard and new treatments for pancreatic cancer\", \u003Cem>Critical Reviews in Oncology/Hematology\u003C/em>, 2015.]\n    \u003C/p>  \n    \u003Cdiv class=\"drug-box-emoji\">🩸🍂\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 储存要求和药品管理📦\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>注射剂型：\u003C/strong>须置于2~8°C冰箱冷藏，避免阳光直射。开封后剩余溶液不得再用。\u003Cbr>\n      \u003Cstrong>药品有效期：\u003C/strong>见外包装，超期必须丢弃。\u003Cbr>\n      \u003Cstrong>化疗药品回收：\u003C/strong>剩余和废弃药液需交由专业机构处理，避免环境污染和家庭二次接触。\u003Cbr>\n      \u003Cstrong>药品搬运：\u003C/strong>建议用盒装或保温袋，避免强烈碰撞和震动。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 漏服与过量处理🔍\u003C/h2>\n    \u003Cp>\n      由于化疗药品均为静脉给药，漏服或误服一般不会发生。在调整方案或延迟周期时，务必由医生根据当前状况决定，并非简单延后即可。\u003Cbr>\n      \u003Cstrong>过量问题：\u003C/strong>若意外过量给药，可能出现重度骨髓抑制和多器官反应，需要立即停药并住院支持治疗。自家不可随意加量或滞后补药。\u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>\n      \u003C/p>\u003Cul>\n        \u003Cli>漏服或提前停药，切忌自定增减剂量，须与主诊医生及时沟通。\u003C/li>\n        \u003Cli>出现药物过量迹象，立即前往有急救设施的医院处理。\u003C/li>\n      \u003C/ul>\n    \u003Cp>\u003C/p>\n    \u003Cspan class=\"drug-mark-quote\">患者使用AG方案7周期后出现乏力、腹泻，提示单一方案长期应用副作用明显，适时调整并紧密观察对后续治疗安全非常关键。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 临床用药案例精要 🎯\u003C/h2>\n    \u003Cp>\n      案例一：70岁女性，完成AG方案7周期后调整化疗药品，出现腹泻、乏力。提示：调整化疗用药需严密观察副作用变化，老年患者更需个体化评估。\u003Cbr>\n      案例二：临床上，如吉西他滨与白蛋白紫杉醇联合用药，剂量设置需根据体表面积合理换算，避免超量并及时监测血象。\u003Cbr>\n      案例三：FOLFIRINOX方案中某患者首次用药后出现手指麻木，后续及时减量，症状缓解。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section drug-summary\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结与安全用药提醒📝\u003C/h2>\n    \u003Cp>\n      胰腺癌肝转移化疗药品（吉西他滨、紫杉醇、FOLFIRINOX等）使用时，安全规范至关重要。务必关注剂型、剂量、周期、特殊人群剂量调整及不良反应处理。每次化疗须严格复查血象和肝肾功能，孕妇及哺乳期女性禁止用药。药品储存安全应按规定操作，过期或剩余药液必须专业处置。遇到任何新症状或用药问题，应第一时间与医生沟通，切勿自行加药或停药。\u003Cbr>\n      只有把握好这些用药细节，才能最大程度提升治疗效果，保障用药安全。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drug-section drug-reference\">\n  \u003Cdiv class=\"drug-section-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">引用文献\u003C/h2>\n    \u003Cul>\n      \u003Cli>Ouyang H, Pan Z, Xie G. Advances in the treatment of pancreatic cancer with liver metastasis. \u003Cem>Frontiers in Oncology\u003C/em>, 2021.\u003C/li>\n      \u003Cli>Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 2011;364(19):1817-1825.\u003C/li>\n      \u003Cli>Neuzillet C, Tijeras-Raballand A, Bourget P, et al. Standard and new treatments for pancreatic cancer. \u003Cem>Critical Reviews in Oncology/Hematology\u003C/em>, 2015;98:166-178.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立全局美术风格命名，确保嵌入安全 */\n.drug-guide-title {\n  font-size: 36px;\n  text-align: center;\n  font-weight: 700;\n  margin-top: 36px;\n  margin-bottom: 20px;\n  color: #246aae;\n  letter-spacing: 2px;\n}\n\n.drug-section {\n  margin: 0 auto 32px auto;\n  border-radius: 14px;\n  max-width: 900px;\n  box-shadow: 0 3px 18px rgba(80, 128, 208, 0.10);\n}\n\n.drug-section-bg {\n  background: linear-gradient(120deg, #f6fbff 0%, #eae7fa 100%);\n  border-radius: 14px;\n  padding: 32px 30px 28px 30px;\n  box-sizing: border-box;\n  min-height: 110px;\n  position: relative;\n}\n\n.drug-section h2 {\n  margin: 0 0 16px 0;\n  font-size: 26px;\n  font-weight: 600;\n  background: linear-gradient(90deg, #cce0ff 55%, #eae7fa 100%);\n  border-radius: 8px;\n  padding: 10px 20px;\n  color: #2067b7;\n  display: inline-block;\n  box-sizing: border-box;\n  /* 淡雅渐变底色 */\n}\n\n.drug-section p {\n  font-size: 18px;\n  color: #374a5e;\n  line-height: 1.9em;\n  margin: 0 0 8px 0;\n}\n\n.drug-section ul {\n  font-size: 16px;\n  margin: 8px 0 12px 20px;\n  padding: 0;\n}\n\n.drug-section li {\n  margin-bottom: 7px;\n}\n\n.drug-box-emoji {\n  font-size: 28px;\n  text-align: left;\n  margin-top: 10px;\n  margin-bottom: -6px;\n}\n\n.drug-mark-quote {\n  display: inline-block;\n  background: #f1ebfa;\n  color: #7151a8;\n  font-size: 17px;\n  font-style: italic;\n  border-radius: 9px;\n  padding: 10px 16px;\n  margin: 15px 0 0 0;\n}\n\n.drug-summary {\n  border-left: 9px solid #6cbde9;\n  background: #f6fcf8;\n}\n\n.drug-section.drug-reference {\n  background: #f1f4f8;\n  border-left: 8px solid #b6cae7;\n}\n\n.drug-reference h2 {\n  color: #5a7fae;\n}\n\n.drug-reference ul {\n  font-size: 16px;\n  margin: 8px 0 0 20px;\n  color: #4163a3;\n}\n\n@media (max-width: 700px) {\n  .drug-guide-title {\n    font-size: 27px;\n    margin-top: 26px;\n    margin-bottom: 10px;\n  }\n  .drug-section-bg {\n    padding: 20px 10px 16px 10px;\n    font-size: 16px;\n    min-height: 70px;\n  }\n  .drug-section h2 {\n    font-size: 17px;\n    padding: 5px 13px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  胰腺癌与肝转移：化疗方案新进展全解——药品安全用药实用指南\n\u003C/div>\n\n\u003Cdiv clas",527,"2025-08-25 18:19:10","胰腺癌, 化疗方案, 肝转移, 吉西他滨, 紫杉醇, FOLFIRINOX, 安全用药, 药物相互作用, 特殊人群用药","探索胰腺癌肝转移的最新化疗方案及其安全用药要点，针对不同患者群体，提供实用指导与专业建议，助力有效治疗。","2025-08-26 13:50:10",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]